Standard BioTools
LAB
84 hedge funds and large institutions have $227M invested in Standard BioTools in 2018 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 27 increasing their positions, 28 reducing their positions, and 15 closing their positions.
44% more call options, than puts
Call options by funds: $189K | Put options by funds: $131K
2.34% more ownership
Funds ownership: 95.42% → 97.77% (+2.3%)
5% more capital invested
Capital invested by funds: $217M → $227M (+$10.3M)
0% more funds holding
Funds holding: 84 → 84 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 15
4% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 28
Top Buyers
Top Sellers
| 1 |
BlackRock
New York
|
-$1.21M |
| 2 |
Goldman Sachs
New York
|
-$813K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$602K |
| 4 |
Millennium Management
New York
|
-$540K |
| 5 |
Morgan Stanley
New York
|
-$498K |
LAB Hedge Fund Activity: Q2 2018 in Review
84 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q2 2018, worth a combined $227M — up 4.7% from $217M a quarter earlier.
Fund positioning in LAB was balanced in Q2 2018: 15 funds opened new positions, 15 closed out, 27 added to existing stakes and 28 trimmed.
The largest buyer was Russell Investments Group, adding an estimated $3.9M. The largest seller was BlackRock, cutting an estimated $1.21M.
- 84 institutional investors held Standard BioTools (LAB) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $227M of Standard BioTools stock for Q2 2018, up 4.7% quarter-over-quarter.
- 15 funds opened new Standard BioTools positions in Q2 2018 and 15 closed out, a net change of 0 holders.
- The largest Standard BioTools buyer in Q2 2018 was Russell Investments Group, an estimated $3.9M added.
- The largest Standard BioTools seller in Q2 2018 was BlackRock, an estimated $1.21M sold.
Based on aggregated 13F filings for Q2 2018.